Filing Flows › Cartesian Therapeutics (RNAC) › Q1 2026
Cartesian Therapeutics (RNAC) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Cartesian Therapeutics (RNAC) reported revenue of $78K for the first quarter 2026 (Q1 2026), -93% from a year earlier and -92% from the quarter before.
Cartesian Therapeutics, Q1 2026: revenue $78K (-93% year over year), net loss $39.2M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $78K | -92% | -93% |
| Operating profit | −$26.5M | — | — |
| Net earnings | −$39.2M | — | — |
| Operating cash flow | −$22.1M | — | — |
What changed
Revenue was $78K in Q1 2026, down 93% year over year and down 92% from the previous quarter.
Operating costs exceeded revenue by $26.5M, an operating margin of -33973.1%. Total costs grew 16% against a revenue fall of 93%. The fastest-growing cost line was Research & development (+33%). The quarter ended with a net loss of $39.2M, narrower than the previous quarter's $92.6M loss.
Operating cash flow was −$22.1M. Non-cash charges added back $600K of depreciation and $2.4M of share-based compensation. Working capital and other items added $14.0M. Capital expenditures of $27K exceeded it, leaving free cash flow of −$22.2M.
Questions
What was Cartesian Therapeutics' revenue in the first quarter 2026?
Cartesian Therapeutics (RNAC) reported revenue of $78K for the first quarter 2026 (Q1 2026), -93% from a year earlier and -92% from the quarter before.